PODCAST

CME

ReachMD

science & medicine medicine

All Episodes

00:00:00

Real-World Evidence of Photobiomodulation Efficacy in...

CME ·

2025/09/16

Faculty: Marion Munk, MD, Ph.D Faculty: David Boyer, MD This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

00:00:00

Clinical and Safety Outcomes from the LIGHTSITE III...

CME ·

2025/09/16

Faculty: David Boyer, MD Faculty: Diana V. Do, MD This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

00:00:00

Patient-Centered Care and Integration of...

CME ·

2025/09/16

Faculty: Diana V. Do, MD Faculty: Marion Munk, MD, Ph.D This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

00:00:00

Integration of Photobiomodulation Therapy into the...

CME ·

2025/09/16

Faculty: David Boyer, MD Faculty: Marion Munk, MD, Ph.D This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

00:00:00

Anatomical Outcomes from the LIGHTSITE III Trial

CME ·

2025/09/16

Faculty: Diana V. Do, MD Faculty: David Boyer, MD This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

00:00:00

Best Practices for Optimized Photobiomodulation...

CME ·

2025/09/16

Faculty: Marion Munk, MD, Ph.D Faculty: Diana V. Do, MD This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

00:00:00

Sustaining Visual Benefits of Photobiomodulation in...

CME ·

2025/09/16

00:00:00

CETP Inhibition with Obicetrapib: Implications for...

CME ·

2025/09/02

Host: Stephen Nicholls, FRACP, FACC, FESC, FAHA This program is intended for health care professionals only. Dr. Stephen Nicholls reveals new data on obicetrapib— showing promise in reducing cardiovascular events.

00:00:00

Risk Stratification and Patient Selection for...

CME ·

2025/08/22

Faculty: Douglas Adkins, MD This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative

00:00:00

Resectable Head & Neck Cancer: A Team-Based Approach...

CME ·

2025/08/22

Host: Robert Haddad, MD Host: Ravindra Uppaluri, MD, PhD Host: Nancy Lee, MD, FASTRO Join our expert panel as they explore the evolving treatment landscape of resectable locally advanced head and neck squamous cell carcinoma. Learn how perioperative immune checkpoint inhibitors are improving event-free survival and get practical insights on applying this data to clinical care. The discussion highlights the importance of early multidisciplinary collaboration and offers

00:00:00

Emerging Evidence for Perioperative ICIs in Locally...

CME ·

2025/08/22

Faculty: Ravindra Uppaluri, MD, PhD This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of

00:00:00

Applying Perioperative ICIs in Clinical Practice

CME ·

2025/08/22

Host: Douglas Adkins, MD This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative

00:00:00

The Evolving Landscape of Resectable Locally Advanced...

CME ·

2025/08/22

00:00:00

Rationale for Combining Radiation and Immunotherapy...

CME ·

2025/08/22

Faculty: Nancy Lee, MD, FASTRO This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of

00:00:00

Managing Immune-Related Adverse Events in the...

CME ·

2025/08/22

00:00:00

Multidisciplinary Collaboration Facilitates...

CME ·

2025/08/22

Faculty: Douglas Adkins, MD Faculty: Ravindra Uppaluri, MD, PhD Faculty: Nancy Lee, MD, FASTRO This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy

00:00:00

Why CELMoDs Matter in Myeloma

CME ·

2025/08/21

Faculty: Sagar Lonial, MD, FACP Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and

00:00:00

Next-Generation Innovations: The Future of CELMoDs in...

CME ·

2025/08/21

Faculty: Noopur Raje, MD Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate

00:00:00

Data Dive: Clinical Evidence Behind CELMoDs

CME ·

2025/08/21

00:00:00

Risk Reduction with GLP-1 RAs in Individuals with...

CME ·

2025/08/21

Host: Brian P. McDonough, MD, FAAFP Guest: Silvio Inzucchi, MD Guest: Darren McGuire, MD, MHSc Subcutaneously-administered GLP-1 RAs have demonstrated cardiovascular and renal risk reduction in individuals with type 2 diabetes at high ASCVD risk; they are recommended in the 2025 ADA Standards of Care as part of the comprehensive approach to cardiovascular and kidney risk reduction. Many individuals with type 2 diabetes are reluctant to initiate or refuse injectable therapy

339 results

CME

All Episodes

Similar Podcasts

Eye On The Sky

Vermont Public

Cienciaes.com

cienciaes.com

This Week in Virology

Vincent Racaniello

Hablando con Científicos - Cienciaes.com

cienciaes.com

The Elective Rotation: A Critical Care Hospital Pharmacy Podcast

Pharmacy Joe